
Joy Baker, MD, FACOG, explains how zuranolone's rapid onset gives clinicians a meaningfully different counseling conversation for PPD.

Joy Baker, MD, OBGYN, FACOG, PMH-C, C-EFM, MT(ASCP), Wellstar West Georgia Medical Center, LaGrange, GA, and co-author of the real-world effectiveness study

Joy Baker, MD, FACOG, explains how zuranolone's rapid onset gives clinicians a meaningfully different counseling conversation for PPD.

The phase 4 study's oversampling of moderate PPD patients, showing a nearly 9-point EPDS drop by day 15, helps close a gap left by trials that enrolled predominantly severe cases.